If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
The Patient Advocate Foundation Resource Library
Year: N/A
As we all know, healthcare can be expensive. So, we have put together some tips to help you use your benefits wisely and get the most value for your money where healthcare is concerned.
As a complementary document to PAF’s Health Insurance Education Series, this tip sheet offers 10 tips to help you get the most out of your health insurance....
Keeping cool when temperatures reach record highs isn’t just about comfort. Dangerously high temperatures can result in heat-related illnesses ranging from heat cramps to heat exhaustion and heat stroke. The following tips can help you keep cool all summer long.
1. Alter your pattern of outdoor exercise to take advantage of cooler times (early morning or late evening). If you can’t change the time of your workout, scale it down by doin...
Heading off to college can be a stressful and chaotic time on its own – but throw a chronic illness (or a few) into the mix and it becomes even trickier to manage all the demands of your day-to-day life. High stress levels or a lack of sleep can easily exacerbate your condition and lead to flare-ups, so it’s important to balance your schedule, plan ahead and make sure you have any accommodations you need to be successful.
To help y...
Graves’ disease is an autoimmune condition and the most common cause of hyperthyroidism in women of childbearing age. It is caused by the patient making an antibody called TRAB (TSH Receptor Antibody) that attacks and turns on the thyroid, making it overactive. TRAB is detectable in the blood of most patients with Graves’ disease. TRAB can pass through to the baby and cause hyperthyroidism after delivery in mothers with Graves’ disease....
Many different illnesses exist, and it is easy for journalists to latch onto the most dramatic and widespread illnesses. Graves’ disease is an incurable condition affecting the thyroid, and related news stories have been found as far back as the late nineteenth century. The aim of this paper is to track newspaper coverage to discern how coverage changed or stayed the same over a period of more than 100 years.
Early newspaper coverage...
Over-activity of the thyroid gland, called hyperthyroidism, can sometimes be caused by a flaw in a person’s immune system (the body’s natural defense system against infection). This problem is a type of autoimmune disorder called Graves’ disease. In addition to thyroid gland over-activity, Graves’ disease causes eye problems in some people, including eye bulging, loss of color vision, double vision, eye pain and dry eyes.
Not e...
Journal of Endocrinological Investigation
Year: 2018
Background:
Graves’ disease (GD) arising after the treatment of toxic multinodular goitre (TMNG) with radioiodine has long been described but it remained unclear whether GD was in fact iodine induced, its incidence, risk factors, natural history and treatment outcomes. Methods: A systematic search using The Cochrane Library, Medline and PubMed Central allowed the pooling of data from 3633 patients with thyroid autonom...
Experimental and Clinical Endocrinology & Diabetes
Year: 2014
Objective:
Antithyroid drug therapy is one of the main medical treatments for Graves’ disease. There have been conflicting reports as to whether the addition of exogenous L-thyroxine improves remission rates more than antithyroid drugs alone. This randomized, controlled and prospective clinical trial was undertaken to investigate the long-term outcome of methimazole treatment with or without exogenous L-thyroxine in Chi...
Purpose:
Improved understanding of thyroid eye disease (TED) pathogenesis has facilitated identification of a targeted molecular approach for TED treatment offering the potential to halt or slow disease progression in a nonsurgical manner. Herein, we provide a summary of the current knowledge of TED management, followed by discussion of a novel insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody and its p...
The Journal of Clinical Endocrinology and Metabolism
Year: 2005
Context:
Radioiodine is an effective and safe treatment for hyperthyroidism but has been implicated as a risk factor for deterioration or new presentation of Graves’ ophthalmopathy (GO). Prophylactic glucocorticoids appear to prevent this effect.
Objective:
The objective of this study was to document the course of GO after radioiodine therapy.
Design:
This...
The Journal of Clinical Endocrinology and Metabolism
Year: 2014
Background:
For patients with active moderate-to-severe Graves’ ophthalmopathy (GO), a course of 4.5 g iv glucocorticoids (GCs) is the recommended therapy. The weekly protocol is preferred because of the potential safety concerns with the daily protocol. However, evidence for the superiority of different administration protocols is lacking.
Methods:
We conducted a prospective, randomized...
European Journal of Endocrinology / European Federation of Endocrine Societies
Year: 2015
Objective:
There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves’ disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.
Design:
A prospective randomized clinical trial with long-term follow-up was conducted to ev...
Thyroid : Official Journal of the American Thyroid Association
Year: 2016
Background:
Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This document describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspecialty physicians and others providing care for patients wi...
Thyroid: Official Journal of the American Thyroid Association
Year: 2017
Background:
Thyroid disease in pregnancy is a common clinical problem. Since the guidelines for the management of these disorders by the American Thyroid Association (ATA) were first published in 2011, significant clinical and scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis...
Graves’ disease (GD) is a systemic autoimmune disorder characterized by the infiltration of thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R)-expressing tissues. Stimulatory autoantibodies (Ab) in GD activate the TSH-R leading to thyroid hyperplasia and unregulated thyroid hormone production and secretion. Diagnosis of GD is straightforward in a patient with biochemically confirmed thyrotoxicosis, positive TSH-...
Thyroid : Official Journal of the American Thyroid Association
Year: 2008
Graves’ orbitopathy (GO) constitutes a major clinical and therapeutic challenge. GO is an autoimmune disorder representing the commonest and most important extrathyroidal manifestation of Graves’ disease, but it may occur in patients without current or prior hyperthyroidism (euthyroid or ophthalmic Graves’ disease) or in patients who are hypothyroid due to chronic autoimmune (Hashimoto’s) thyroiditis. Although the pathogenesis of GO (5...
Journal of Endocrinological Investigation
Year: 2015
Graves’ disease is the most frequent form of hyperthyroidism in iodine sufficient countries, and Graves’ orbitopathy (GO) is its most important and common extrathyroidal manifestation, affecting about 25 % of patients. Although GO is generally mild and rarely progressive, thyroid dysfunction, both hyperthyroidism, and hypothyroidism, can influence its course. GO has been reported to improve after correction of hyperthyroidism with antithyr...
Clinical Medicine: Journal of the Royal College of Physicians of London
Year: 2015
Graves’ orbitopathy (GO) is uncommon, but responsible for considerable morbidity. A coordinated approach between healthcare professionals is required in order to meet the needs of patients. Early diagnosis can be achieved by a simple clinical assessment. Low-cost effective interventions can be initiated by generalists, which may improve outcomes. Moderate-to-severe GO should be referred to specialised centres. Recommendations for clinical diag...
American Journal of Obstetrics & Gynecology
Year: 2018
Objective:
To determine the impact of maternal and fetal thyroid-stimulating immunoglobulin (TSIG) as predictors of neonatal thyroid dysfunction in pregnancies complicated by Graves’ disease.
Study Design:
This prospective cohort study was conducted at The University of Iowa Hospital and Clinics. We analyzed all women with a history of Graves’ disease with confirmed elevated TSIG at the...
History:
A 20-yr male college football player presented to the athletic training room with 15 pounds of unexplained weight loss over a two-week period. He reported decreased appetite, increased general fatigue and muscle fatigue over the past two weeks. His review of systems was otherwise negative. He had no chronic medical problems or current medications. His family history was significant for asthma, hypertension, and...
Introduction:
The cardiovascular system function is modulated by thyroid hormone levels. The antibodies involved in Graves’ disease are central to the pathophysiological consequences of the disease but the impact of their evolution over time is still an area of interest.
Aim:
To evaluate the relationship between thyroid function, autoimmunity, insulin resistance and cardiovascular risk...
The diagnosis of Graves’ disease (GD) is traditionally based on the clinical features of persisting hyperthyroidism, enlarged thyroid gland, and often the presence of ophthalmopathy. However, when the clinical presentation of thyrotoxicosis is not diagnostic of GD, the 2011 American Thyroid Association guideline recommends “a radioactive iodine uptake scan should be performed”. Although it is long recognized that Thyrotropin (TSH) recept...
Graves’ disease is an autoimmune condition affecting the thyroid gland and is a common cause of hyperthyroidism. The main treatment goals are the reduction in thyroid hormone overproduction either with antithyroid drugs (ATD), surgery or radioactive iodine (RAI) therapy.
The aim of RAI (I-131) therapy is to treat hyperthyroidism by destroying sufficient thyroid tissue to render the patient either euthyroid or hypothyroid. The objecti...
There are three effective treatments for Graves Disease (GD): thyroidectomy, radioactive iodine, and antithyroid drugs. These options differ in their efficacy, safety, convenience, and costs; none is clearly superior to the others for all patients. Practice patterns, however, suggest that patients are more likely to receive a particular mode of therapy depending on where they receive care. This inconsistency of practice suggests that GD patien...
A healthy 52-year-old woman has had persistent palpitations recently. Serum TSH is < 0.02 mIU/mL (reference, 0.3-4.7 mIU/mL), free T4 is 5.70 ng/dL (reference, 0.8-1.7 ng/dL), and free triiodothyronine (T3) is 1920 pg/dL (reference, 222-383 pg/nL). She has fine bilateral hand tremors and sinus tachycardia. How do we work up this new diagnosis of thyrotoxicosis?
This is one of the most common consults we receive. Thyroid antibodies m...
Early Symptoms
TED can first present with signs or symptoms such as sensitivity to light, a feeling of grittiness in the eyes, excessive tearing, eye pain, or dry eyes. However, these symptoms are often confused with other conditions, such as allergies or dry eye symptoms. Evidence shows that even these first, seemingly mild symptoms can negatively affect patient quality of life. Overlooking them can lead to unnecessary...
Epidemiology:
Most common cause of Thyrotoxicosis in the United States (up to 60-80% of cases).
Pathophysiology:
• Autoimmune disorder.
• Thyroid stimulating antibodies bind TSH receptors, resulting in Thyroid hormone synthesis and release.
Risk Factors:
• Female gender.
• Autoimmune Disorder (or Family History of autoimmune disorder)....
This indispensable volume is designed to facilitate the best possible physician–patient discussion on Graves’ disease by providing the most up-to-date evidence-based information in a clinically useful and patient-centric manner. Comprehensive and covering such topics as Professionalism and the Art of Patient-centric Thyroidology, the Immunopathogenesis of Graves’ Disease, and the Diagnosis and Management of Thyroid Storm, the book addres...
Graves’ disease is the most common cause of hyperthyroidism (overactive thyroid). It usually affects people between 30-60 years of age and is much more common in women than men. Patients with Graves’ disease, often have enlarged thyroids (goiter) and bulging eyes (exophthalmos). There are three main options to treat Graves’ disease: antithyroid drugs (ATDs), radioactive iodine therapy and surgery.
The most common ATDs in use are...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
a confirmation email has been sent to your inbox. click the link in the email to activate your account. can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password. can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
The symptoms and treatments for Graves' disease and thyroid eye disease vary, depending on which conditions a patient has been diagnosed with. Select which type you want to learn more about, and oneGRAVESvoice can highlight the resources that are most relevant to you.